Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$13.66
▲ $0.01 (+0.1%)
Market data updated: 09/16 10:14 AM
Fundamentals updated: 09/15/2026
News analyzed: 09/16/2026
Market Cap
Not available
Day Range
$13.65 - $13.68
52-Week Range
$5.69 - $13.79
Beta
—
Next Earnings
09.11.2026
OGN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+31.5% (1Y)
Strengths: 10/29 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Daily volatility (ATR)
ATR: 0.3% of price
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: -$0.06 vs. price $13.66 (-100.5%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
49
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
26
Quality
50
Value
38
Momentum
56
Risk
50
Sentiment
68
Fundamental
57
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Organon & Co.** has primarily focused on its women’s health initiatives, particularly the launch of the **Can-RISE study**—a national research project on menopause, funded by the company—and the **REMS (Risk Evaluation and Mitigation Strategy) program** for its drug **MIUDELLA®**, ahead of commercial release. Additionally, there was a report on a U.S. Representative selling a significant amount of Organon stock, though no direct company-related news was provided beyond this. The coverage reflects a focus on regulatory milestones and research advancements in women’s health.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Organon & Co.. News trend score: 68. Reason: 5 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
28
🎯 Conviction (vs. Emotion)
38
Psychology
84
Fundamentals
57
Technical
56
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+2%
Market Narrative
51
Fundamental Reality
38
Narrative Gap
+13
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
OGN’s psychology is dominated by anchoring, with traders fixated on the 0.3% gap below resistance, suggesting rigid price expectations. Confirmation bias and mild euphoria coexist, as positive momentum and narrative gaps reinforce selective attention to favorable data. The low panic/selling score and neutral volatility imply no urgency, while FOMO remains muted despite modest tailwinds. The key question: will traders break the resistance anchor, or will the narrative gap widen further?
Updated: 09/09/2026, 02:32 PM
What could change this?
👥 What the crowd believes
"National Can-RISE Study... supported by a charitable grant from Organon to close gaps in menopause research"
"Jeannette Jager-van Dijk appointed CEO of Arletta Pharma Solutions, focusing on Lybrido™’s Phase 2 MONARCH study"
"Organon opens REMS Program for MIUDELLA® ahead of commercial availability"
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 80/100
🔴 Weakest match
Peter Lynch — 0/100
🗣️ Why do they disagree?
Based on the documented principles of each methodology, the model estimates that the higher scores from Burton Malkiel & John Bogle (60) and Jesse Livermore (60) reflect a relatively neutral view, emphasizing limited evidence for outperformance and a lack of clear trend. In contrast, the moderate scores from Gerald Loeb (55), Charles Mackay (51), and Jack Schwager (51) point to some risk and crowd dynamics but no decisive edge. The lower scores from investors focused on safety and valuation—such as Howard Marks (36), Benjamin Graham (24), and Philip Fisher (0)—indicate that the stock fails key defensive, quality, and growth‑at‑reasonable‑price criteria, flagging it as potentially overbought, volatile, or insufficiently stable. Overall, the divergence stems from whether the methodology prioritizes market efficiency and short‑term signals versus long‑term safety and intrinsic value.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 80
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 60
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 57
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 55
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 51
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 38
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 36
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 33
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 33
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 32
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 31
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 26
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 24
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 0
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (5 bullish · 5 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a trading range, but the picture isn't yet clear enough on the likely direction.
Low confidence
$13.46
Range Bottom
$13.78
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
53.3%
Operating Margin
—
Net Margin
3.0%
EBITDA Margin
—
ROE
24.9%
ROA
1.5%
ROIC
—
EPS
$0.72
Cash
$574.00M
Total Debt
$8.64B
Current Ratio
1.82
Debt/Equity
11.49
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 14.8.2026 | $0.020 |
| 11.5.2026 | $0.020 |
| 10.5.2026 | $0.020 |
| 23.2.2026 | $0.020 |
| 22.2.2026 | $0.020 |
| 20.11.2025 | $0.020 |
| 19.11.2025 | $0.020 |
| 15.8.2025 | $0.020 |
| 14.8.2025 | $0.020 |
| 12.5.2025 | $0.020 |
| 11.5.2025 | $0.020 |
| 24.2.2025 | $0.280 |
How is Fair Value calculated? →
Current Price
$13.66
Estimated Fair Value (DCF)
-$0.06
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-100.5%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
0.3%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 0.3% | $539.36M | $494.82M |
| 2 | 0.8% | $543.75M | $457.66M |
| 3 | 1.4% | $551.23M | $425.65M |
| 4 | 1.9% | $561.91M | $398.07M |
| 5 | 2.5% | $575.96M | $374.33M |
Base FCF (last actual year)
$538.00M
Terminal Value
$9.08B
Present Value of Terminal Value
$5.90B
Enterprise Value
$8.05B
Net Debt
$8.07B
Equity Value
$-16.49M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$2.88
Tangible Book Value per Share (Tangible NAV)
-$17.38
Sentiment based on basic keywords (not AI) — 5 positive, 13 neutral, 2 negative out of the last 20 articles.
Yahoo · 14.9.2026
SeekingAlpha · 12.9.2026
Yahoo · 10.9.2026
Zacks · 8.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 1.9.2026
Yahoo · 1.9.2026
Yahoo · 27.8.2026
GlobeNewswire · 27.8.2026
SeekingAlpha · 24.8.2026
SeekingAlpha · 16.8.2026
GlobeNewswire · 13.8.2026
Benzinga · 13.8.2026
Business Wire · 11.8.2026
Argus Research · 4.8.2026
SeekingAlpha · 31.7.2026
Zacks · 31.7.2026
Zacks · 31.7.2026
Associated Press · 31.7.2026
Business Wire · 31.7.2026
Organon & Co. (OGN) currently has a StockIQ AI score of 49/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
OGN currently scores 49/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, OGN's estimated fair value is -$0.06, which is 100.5% below the current price of $13.66. This is one valuation model among several signals in the fair-value category, not a price target.
OGN's technical score is 56/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: ATR: 0.3% of price; Return on equity (ROE): 24.9% — strong; Current ratio: 1.82.
Based on the real signals StockIQ computed: Estimated fair value: -$0.06 vs. price $13.66 (-100.5%); Calmar: -0.15 (3y annualized return -11.2% / max drawdown 75.2%); Revenue growth (last year): -2.9%.
Yes — OGN has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Arjona Ferreira Juan Camilo | Tax Withholding in Shares | 11.8.2026 | 4,134 | -4,134 | $13.62 |
| Arjona Ferreira Juan Camilo | Exercise of Derivative Securities | 11.8.2026 | 11,519 | +11,519 | — |
| Arjona Ferreira Juan Camilo | Exercise of Derivative Securities | 11.8.2026 | 11,519 | +11,519 | — |
| Arjona Ferreira Juan Camilo | Tax Withholding in Shares | 11.8.2026 | 37,432 | -4,134 | $13.62 |
| Arjona Ferreira Juan Camilo | Exercise of Derivative Securities | 11.8.2026 | 41,566 | +11,519 | — |
| Arjona Ferreira Juan Camilo | Exercise of Derivative Securities | 11.8.2026 | 0 | +11,519 | — |
| Drinane Juliana Papa | Open Market Sale | 5.8.2026 | 14,761 | -14,761 | $13.57 |
| Drinane Juliana Papa | Open Market Sale | 5.8.2026 | 18,475 | -14,761 | $13.57 |
| Ezekowitz Alan | Grant/Award from Employer | 12.6.2026 | 17,857.143 | +17,857.143 | $13.44 |
| ESSNER ROBERT | Grant/Award from Employer | 12.6.2026 | 17,857.143 | +17,857.143 | $13.44 |
| Gayle Helene D | Grant/Award from Employer | 12.6.2026 | 17,857.143 | +17,857.143 | $13.44 |
| LAZARUS ROCHELLE B | Grant/Award from Employer | 12.6.2026 | 17,857.143 | +17,857.143 | $13.44 |
| Leone Deborah R | Grant/Award from Employer | 12.6.2026 | 17,857.143 | +17,857.143 | $13.44 |
| Ozuah Philip | Grant/Award from Employer | 12.6.2026 | 17,857.143 | +17,857.143 | $13.44 |
| Patton Cynthia M | Grant/Award from Employer | 12.6.2026 | 17,857.143 | +17,857.143 | $13.44 |
| Sequeira Ramona | Grant/Award from Employer | 12.6.2026 | 17,857.143 | +17,857.143 | $13.44 |
| Sharp Shalini | Grant/Award from Employer | 12.6.2026 | 17,857.143 | +17,857.143 | $13.44 |
| LAZARUS ROCHELLE B | Grant/Award from Employer | 12.6.2026 | 81,141 | +17,857 | $13.44 |
| ESSNER ROBERT | Grant/Award from Employer | 12.6.2026 | 81,141 | +17,857 | $13.44 |
| Sharp Shalini | Grant/Award from Employer | 12.6.2026 | 81,496 | +17,857 | $13.44 |
| Gayle Helene D | Grant/Award from Employer | 12.6.2026 | 81,141 | +17,857 | $13.44 |
| Patton Cynthia M | Grant/Award from Employer | 12.6.2026 | 81,141 | +17,857 | $13.44 |
| Ezekowitz Alan | Grant/Award from Employer | 12.6.2026 | 81,141 | +17,857 | $13.44 |
| Sequeira Ramona | Grant/Award from Employer | 12.6.2026 | 39,951 | +17,857 | $13.44 |
| Leone Deborah R | Grant/Award from Employer | 12.6.2026 | 81,141 | +17,857 | $13.44 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
16,695,178 shares short as of 2026-08-31 · vs. 16,806,674 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
52.5% of trading volume this week was short selling, vs. 81.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology